Advertisement

Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study)

  • J. Alexieva-Figusch
  • W. L. J. van Putten
  • H. A. van Gilse
  • J. Blonk- V. D. Wijst
  • J. G. M. Klijn
Articles

Abstract

The progestin megestrol acetate and the anti-estrogen tamoxifen are used as effective drugs in the treatment of metastatic breast cancer and have few side effects. The sequence and indications for use in practice still need to be defined. Of 219 postmenopausal patients with metastatic breast cancer and measurable lesions, 136 were treated with megestrol acetate (MA) per os (180 mg daily) and followed by tamoxifen (TAM) (40 mg daily) in cases with progression, and 83 patients were treated with the inverse drug regimen. In the first line treatment they showed similar effects: MA caused remission in 31/136 patients (23%) and TAM in 17/80 patients (22%) (mean duration 12 and 13 months respectively), while as a second treatment line MA caused remission in 14/83 patients (17%) and TAM in 12/132 patients (9%), which was not significant (P=0.10). Also with respect to survival there was no significant difference between the two treatment modalities.

Key words

Breast cancer Tamoxifen Megestrol acetate 

References

  1. 1.
    Mouridsen H, Palshof T: Tamoxifen in advanced breast cancer.Cancer Treatment Rev 5, 131 (1978).CrossRefGoogle Scholar
  2. 2.
    Alexieva-Figusch J, Gilse H A van, Hop W C J, Phoa C H, Blonk-v.d.Wijst J, Treurniet R E: Progestin therapy in advanced breast cancer: megestrol acetate —an evaluation of 160 treated cases.Cancer 46, 2369 (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    Alexieva-Figusch J, Blankenstein M A, Hop W C J, Klijn J G M, Lamberts S W J, de Jong F H, Docter R, Adlercreutz H, van Gilse H A: Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.Eur J Cancer 20, 33 (1984).CrossRefGoogle Scholar
  4. 4.
    Mattsson W, Von Heyben F, Hallsten L, Tennvall L: A phase III study of tamoxifen versus high dose medroxyprogesterone acetate (HD-MPA) in post-menopausal advanced breast cancer.Int Symp on MPA. Geneva, 24–25 February 1982.Excerpta Medica 276 (1982).Google Scholar
  5. 5.
    Beretta G. Tabiadon D, Luporini G: Clinical experience with medroxyprogesterone acetate in advanced breast cancer.Int Symp on MPA. Geneva, 24–25 February 1982.Excerpta Medica 285 (1982).Google Scholar
  6. 6.
    Camaggi C M: In F. Cavalliet al (eds): Round Table.Int Symp on MPA. Geneva, 24–26 February 1982.Excerpta Medica 185 (1982).Google Scholar
  7. 7.
    Hayward J L, Carbone P P, Heuson J C, Kumaoka S, Segaloff A, Rubens R D: Assessment of response to therapy in advanced breast cancer.Eur J Cancer 13, 89 (1977).Google Scholar
  8. 8.
    Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, Mantel N, McPherson K, Peto J, Smith P G: Design and analysis of randomised clinical trials requiring prolonged observation of each patient.Br J Urol 45, 586 (1977).Google Scholar
  9. 9.
    Fabian C, Sternson L A: Tamoxifen pharmacokinetics in patients with breast cancer: comparison of traditional and loading dose schedules.Reviews on Endocrine-Related Cancer, Suppl. 9, October, 155 (1981).Google Scholar

Copyright information

© Humana Press Inc. 1985

Authors and Affiliations

  • J. Alexieva-Figusch
    • 1
  • W. L. J. van Putten
    • 2
  • H. A. van Gilse
    • 1
  • J. Blonk- V. D. Wijst
    • 1
  • J. G. M. Klijn
    • 1
  1. 1.Department of Internal Medicine and EndocrinologyDr Daniel den Hoed Cancer Center/Rotterdam Radio-Therapeutic InstituteRotterdamThe Netherlands
  2. 2.Department of BiostatisticsDr Daniel den Hoed Cancer Center/Rotterdam Radio-Therapeutic InstituteRotterdamThe Netherlands

Personalised recommendations